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ABSTRACT: Microbubbles and microcapsules of silane-polycaprolactone (SiPCL) have been filled with a fluorescent acrid-
ium salt (lucigenin) as a model for a drug loaded delivery vehicle. The uptake and delivery was studied and compared with 
similar microbubbles and microcapsules of silica/mercaptosilica (S/M/S). Positively charged lucigenin was encapsulated 
through an electrostatic mechanism, following a Type I Langmuir isotherm as expected, but with additional multilayer 
uptake that leads to much higher loading for the SiPCL system (~280 µg/2.4 × 109 microcapsules compared with ~135 µg/2.4 
× 109 microcapsules for S/M/S). Whereas lucigenin release from the S/M/S bubbles and capsules loaded below the solubility 
limit is consistent with diffusion from a monolithic structure, the SiPCL structures show distinct release patterns; the 
Weibull function predicts a general trend for diffusion from normal Euclidean space at short times tending towards diffu-
sion out of fractal spaces with increasing time. As a slow release system, the dissolution time (Td) increases from 1 – 2 days 
for the S/M/S and the low concentration loaded SiPCl vehicles to ~10 days for the high loaded microcapsule. However, the 
Td can be reduced on insonation to 2 days, indicating the potential to gain control over local enhanced release with ultra-
sound. This was tested for a docetaxel model and its effect of C4-2B prostate cancer cells, showing improved cell toxicity 
for concentrations below the normal EC50 in solution. 
1. Introduction  
Ultrasound has become one of the most used medical im-
aging methodologies in the world1,2, since it is safe, non-
invasive, low risk, portable and comparatively low cost, of-
fers results in real-time and is relatively easy to use.  How-
ever, in some cases it is limited in its application by image 
contrast. We have previously reported on a silica/polymer 
layered composite, formulated into a microbubble geome-
try, equivalent to the classical ultrasound contrast agent, 
that can be visualized and located by ultrasound as a result 
of the shell-gas backscatter contrast.3 However, this silane-
polycaprolactone (SiPCL) microcapsule also offers a versa-
tile material matrix to carry active materials (e.g. drugs), 
since the silane derivatives can be modified and chosen to 
enhance or weaken interactions with the desired payload. 
Furthermore, as shown previously, lipase-catalyzed hy-
drolysis of the PCL provides a route to biodegradation and 
full dispersal of the spent vehicle matrix.3 In terms of mi-
crocapsule loading, there could however, be clear disad-
vantages with the capacity of this geometry, since the ma-
trix is confined to a thin layer, encapsulating the insona-
tion-sensitive gas bubble, or dried to the inside or outside 
of the bubble. Nevertheless, PCL has been reported previ-
ously to be a good absorbent for polar organic compounds 
due to its ability to form hydrogen bonds and participate 
in electron donor-electron acceptor interactions.4 In drug 
delivery applications, PCL has also been seen to work well 
in sequestering hydrophobic drugs5,6, so that its potential 
as a drug carrier is clear, despite the possible limitations of 
a bubble geometry. 
To examine the viability of a microbubble geometry to act 
as a payload carrier, a model compound has been chosen 
as a drug surrogate. The acridine nucleus7 is found in a 
wide variety of drugs, offering, for example, antibacterial, 
antiprotozoal and antimalarial agents, but also acridine de-
rivatives have been shown to possess activities as anti-in-
flammatory and anticancer agents.8 The latter builds on 
the ability of the acridine chromophore to intercalate DNA 
and inhibit topoisomerase enzymes. Lucigenin (bis-N-
methylacridinium nitrate) is a useful first model for this 
class of compound due to its fluorescence properties, so 
that encapsulation and release can be easily quantified. Lu-
cigenin has been shown to adsorb to silica microparticles 
through electrostatic interactions – at neutral pH, luci-
genin is positively charged while the silica microparticles 
have negatively charged silanols on their surfaces (the iso-
electric point of silica is ~ pH 2).9,10 This provides a conven-
ient model for the loading of positively charged drugs. 
Overall, positively charged molecules have been reported 
to be encapsulated into silica through this electrostatic 
mechanism, and to follow a Type I Langmuir isotherm.9,11–
13  
 One of the issues in drug administration is the balance be-
tween the delivery of a burst concentration and a sustained 
delivery over extended periods.14 These challenges are now 
central to the drug delivery vehicle design, along with 
mechanisms for triggering release on demand.  For exam-
ple, following encapsulation, increasing the solution pH 
might induce the release of lucigenin through desorption9, 
but there has been no information thus far on the potential 
for enhanced ultrasound triggered release. 
The work reported herein examines the loading curves for 
air-filled microbubbles with and without the enzyme de-
gradable SiPCL component, using established models, to 
consider the mechanism of lucigenin delivery. For compar-
ison, delivery from microcapsules (still filled with luci-
genin solution) was compared to observe the effect of mi-
crocapsule desiccation to form microbubbles, and the im-
pact of ultrasound was considered as a potential triggering 
mechanism and then tested with the drug, docetaxel. 
Understanding of in vitro release kinetics is a prerequisite 
for establishing the in vitro−in vivo relationship, to guide 
the formulation for performance in vivo.  The loading and 
release of material from polymeric matrices has been stud-
ied extensively, especially in the pharmaceutical industry 
for the development of drug delivery vehicles. In the case 
of nanoparticles, many methods employ diffusion across a 
dialysis membrane that contains the particles15, but for the 
larger microparticles, as studied here, centrifugation or fil-
tration has been used. More importantly, modelling of the 
release profiles has resulted in the development of multiple 
empirical and semi-empirical equations. Of these, one of 
the most well-known is the Higuchi equation, studied for 
a planar vehicle releasing payload through Fickian diffu-
sion. The simplicity of the Higuchi equation is attractive 
and it was modified by Baker and Lonsdale in 1974 to de-
scribe drug release from a spherical matrix, but neverthe-
less, more complex matrices with multilayer structure have 
led to increased complexity of the models as well as empir-
ical model use.16,17 These models form the basis for exami-
nation of payload release here. 
 
2. Experimental 
2.1 Materials  
All chemicals were purchased from Sigma-Aldrich Com-
pany LLC (Dorset, UK). Cell culture media was purchased 
from Life Technologies (Thermo Fisher Inc., Leicester-
shire, UK). Cell culture plates and well plates were pur-
chased from TTP Techno Plastics Products AG (Tra-
sadingen, Switzerland). Cell culture microscope slides 
were obtained from ibidi GmbH (Martinsried, Germany). 
C4-2B cells were obtained from the Biorepository and Cell 
Services at the Cancer Research UK Cambridge Institute.  
 
2.2 SiPCL Synthesis 
The synthesis of SiPCL followed the protocol given by Tian 
et al.18,19 Polycaprolactone diol (PCL diol, Mn 2000 g/mol) 
was end-capped with alkoxysilane groups for sol-gel func-
tionality using 3-(trimethoxysilyl)propyl isocyanate 
(IPTES) and 1,4-diazobicyclo[2,2,2]octane (DABCO). The 
molar ratio used was 1:3:2. PCL diol and DABCO were 
mixed and heated to 70°C in a round bottom flask under 
reflux. IPTES was added to start the reaction and the reac-
tion was carried out for 22 – 24 hours. The product, SiPCL, 
was collected by precipitation in methanol and filtered be-
fore drying overnight by vacuum desiccation. Successful 
synthesis of the SiPCL polymer was determined by Fourier-
transform infrared spectroscopy (FT-IR) (Figure S.1).  
 
2.3 Polystyrene template synthesis  
The polystyrene microparticle template was fabricated us-
ing dispersion polymerization according to Lin et al.20 Eth-
anol (134 mL), water (6.9 mL), styrene (50.6 mL), 4-styrene 
sulfonic acid (0.37 g), poly(acrylic acid) (2.26 g), and azo-
bisisobutyronitrile (1.0 g) were mixed together in a round 
bottom flask under reflux at low stirring speed and de-
gassed by bubbling with N2. The reaction was initiated by 
heating to 80°C and stopped at 24 hours by cooling on ice 
for 5 minutes. The polystyrene was collected by centrifuga-
tion and washed with ethanol. To render the polystyrene 
positively charged, 0.5 w/v% polystyrene was incubated in 
1 w/v% poly(allylamine hydrochloride) (PAH) solution. 
The excess PAH was washed off with water. The diameter 
of the particles, measured by transmission electron micros-
copy (TEM) was in a range of 2243 ± 65 nm. 
 
2.4 Sol-gel fabrication of microcapsules and microbubbles 
Microcapsules were synthesized using the modified Stöber 
sol-gel method as described by Lu et al.21 and Lin et al.20 
and modified by Tsao and Hall3.  A typical reaction con-
sisted of the following: isopropanol (20 mL), water (3.5 
mL), ammonium hydroxide (0.5 mL, 28.0-30.0% NH3 ba-
sis), PAH-modified polystyrene (0.026 g), SiPCL (0.2 – 
0.4 g) dissolved in 1 mL tetrahydrofuran (THF), and tetra-
ethyl orthosilicate (TEOS) (0 – 214 µL). All chemicals ex-
cept SiPCL and TEOS were first pre-mixed in an Erlen-
meyer flask. To start the reaction, SiPCL solution was 
added dropwise, followed at 5 minutes by TEOS solution. 
The reaction was left to stir at room temperature for 5 
hours, except for the 50 wt% SiPCL formulation, which was 
stopped at 3 hours. The reaction was terminated by re-
moval from the solution through centrifugation. The re-
sulting polystyrene/SiPCL/silica core/shell microparticles 
were washed with isopropanol, and the polystyrene was re-
moved by incubation with THF. This resulted in a hollow 
SiPCL/silica microcapsule filled with THF. Vacuum desic-
cation could be used to remove the THF and to fill the 
structure with air to form microbubbles.  
To make silica/mercaptosilica/silica (S/M/S) microcap-
sules, the ammonium hydroxide was increased to 4 mL of 
the 28.0 – 30.0% NH3 basis solution. To start the sol-gel re-
action, 1000 µL of TEOS was added, followed at 1 hour by 
492 µL of (3-mercaptopropyl)trimethoxysilane (MPTMS) 
and 776 µL of TEOS at 1.5 hours. The microcapsules were 
collected at 3 hours and processed in the same manner as 
the SiPCL microcapsules.  
  
2.5 Chemical characterization methods 
FT-IR was conducted on a Perkin Elmer Spectrum One FT-
IR Spectrometer (Perkin Elmer Inc., MA, USA) with an at-
tenuated total reflectance sampling accessory attached. 
The spectra were read from 550 – 4000 cm-1.  
Imaging of microcapsules/microbubbles was conducted 
using TEM on a Technai G2 80-200 kV microscope (FEI, 
OR, USA) at 120 kV. Measurements were taken using Im-
ageJ image processing software (National Institutes of 
Health, MD, USA).  
Sessile drop contact angle measurements were made on 
approximately 8 × 107 microbubbles dried from 10 µL of mi-
crocapsule solution. A DataPhysics OCA 20 Contact Angle 
System (DataPhysics Instruments GmbH, Filderstadt, Ger-
many) was used to monitor the change in 3 µL water drop-
lets at a frame rate of 8.14 frames/second.  
Dynamic light scattering (DLS) measurements were con-
ducted on a Malvern Nano-ZS Zetasizer (Malvern Instru-
ments Ltd., Worcestershire, UK). 
 
2.6 Lucigenin and docetaxel encapsulation  
Lucigenin was encapsulated into microcapsules by batch 
incubation of microcapsules in lucigenin in water solution. 
A stock solution of 2000 µg/mL was used. Isopropanol-
filled capsules were first washed with water before encap-
sulation at room temperature with shaking overnight in 
batches of 2.4 × 109 microcapsules. The microbubbles were 
incubated in 1 mL of a solution of the appropriate lucigenin 
concentration (diluted in water). Centrifugation was used 
to separate out the microcapsules from the excess luci-
genin solution. To form microbubbles, the microcapsules 
were dried under vacuum desiccation over 2 days.  
Lucigenin concentration was determined by comparing 
the fluorescent emission of the supernatant solution to a 
12-point calibration curve (0 - 3.0 µg/mL, R2 = 0.9977, de-
tection limit = 0.002 µg/mL, Figure S.2). An excitation 
wavelength of 370 nm was used, while emission was col-
lected from 450 nm to 600 nm. 
A 1 mg/mL docetaxel stock solution was made in ethanol. 
Docetaxel encapsulation was conducted in a similar man-
ner to lucigenin encapsulation with 2.4 × 109 microcap-
sules. Microcapsules were washed once with ethanol be-
fore being resuspended and incubated in 1 mL of docetaxel 
solution overnight at room temperature with agitation.  
Docetaxel concentration was determined by UV absorb-
ance at 230 nm using a Nanodrop 1000 spectrophotometer 
(Thermo Fisher Scientific Inc., Leicestershire, UK). A 6-
point calibration curve was made in ethanol and was found 
to be linear between 1 – 70 µg/mL (R2 = 0.9995, detection 
limit = 1 µg/mL, Figure S.3).  
 
2.7 Lucigenin delivery  
To understand the release behavior of lucigenin from luci-
genin-loaded microcapsules and microbubbles, the sam-
ples were tested in an open system of flowing aqueous me-
dia. Experiments were conducted in phosphate buffered 
saline (PBS), which closely matches physiological pH, os-
molarity, and ion concentrations. The sustained delivery of 
lucigenin was investigated at 37°C in 0.01 M PBS. The re-
lease of lucigenin for short time (3 hours) was investigated. 
A separate 12-point calibration curve was made for luci-
genin in PBS due to the quenching of fluorescence by chlo-
ride ions (0 – 3.0 µg/mL, R2 = 0.9982, detection limit = 
0.005 µg/mL, Figure S.4). The short-term sustained deliv-
ery of lucigenin was investigated using an open system 
which consisted of a continuous flow of fresh 0.01 M PBS 
at a rate of 1 mL/minute.  
The release of lucigenin was tested from both 50 wt% 
SiPCL and S/M/S microcapsules (solution-filled) and mi-
crobubbles (air-filled) for over 180 minutes (3 hours). 
A syringe filter was used as a flow cell. The lucigenin-
loaded sample (2.4 × 109 microcapsules or microbubbles) 
was suspended in 300 µL of PBS to be loaded into the flow 
cell. The microcapsules and microbubbles were loaded 
into the flow cell prior to the start of the experiment. This 
was then connected to a Gilson Minipuls 2 peristaltic pump 
(Gilson Scientific Ltd., Bedfordshire, UK). The tubing and 
flow cell were immersed in a 37°C water bath throughout 
the experiment. The experiment was run for 3 hours. The 
lucigenin release recorded at very short time (circa 1 mi-
nute) included the first data before flow was started. The 
run-off was collected to determine the lucigenin released 
in each time frame. Two loading conditions were selected 
for the release studies – 500 µg/mL and 100 µg/mL. Only 
the 50 wt% SiPCL and S/M/S microbubbles were investi-
gated. The details are presented in Table 2.  
 
2.8 Ultrasound triggered delivery  
The effect of ultrasound insonation on lucigenin delivery 
from microbubbles was investigated using the Terason 
t3000 portable ultrasound (Teratech Corporation, MA, 
USA).  This study was confined to this portable instrument 
due to limitations in instrumentation that could be moved 
between tissue culture suites and open laboratory. A linear 
12 – 5 MHz transducer (12L5) was used. The Terason Ultra-
sound System (Version 4.1.0) was used to control the trans-
ducer. The experiments were conducted using the same 
flow-cell set-up as the sustained delivery experiments. The 
ultrasound probe was placed in the 37°C water bath at a 
distance where the flow cell was in the center of the ultra-
sound image. Ultrasound insonation was conducted under 
the “high” frequency setting, which was measured to be ap-
proximately 7.3 MHz (Figure S.5) and mechanical index 
(MI) <0.8. Ultrasound insonation was started 30 minutes 
after flow of PBS was started. Samples were collected every 
5 minutes for a total of 30 minutes of continuous insona-
tion and analyzed for differences in lucigenin concentra-
tion. 
 
 
 
 2.9 Cell culture and viability  
C4-2B cells were cultured in Roswell Park Memorial Insti-
tute 1640 media supplemented with 10% fetal bovine serum 
and L-glutamine. Cells were plated on 150 mm tissue cul-
ture plates and grown at 37°C and 5% CO2 in a Heracell 150 
incubator (Thermo Fisher Scientific Inc., Leicestershire, 
UK). Biocompatibility and drug delivery experiments were 
done in 96-well plates. Cells were plated at a density of 1500 
cells/well with 90 µL media and incubated for 24 hours to 
allow for adhesion. Subsequently, 10 µL treatment solution 
was added for a total volume of 100 µL media in each well 
and allowed to incubate for 24 to 72 hours. The MTS assay 
was used to determine cell viability. Cells were incubated 
for 2 hours for the assay to develop and readings were 
taken at 490 nm. See Supporting Information for more de-
tails on the viability assay.  
 
2.10 Incorporation of microbubbles into cells 
For initial fluorescence experiments, C4-2B prostate cancer 
cells were plated on 100 mm dishes with 10 mL media and 
grown to confluency. Lucigenin-filled microbubbles were 
incubated with C4-2B cells at a concentration of 2 × 106 mi-
crobubbles/mL for 48 hours (a concentration of approxi-
mately 3.2 x 108 microbubbles/mL is equivalent to one dose 
of commercial ultrasound contrast agent). The microbub-
ble-incubated cell samples were washed with PBS and re-
suspended in 10 mL media for fluorescence imaging. Incor-
poration was examined using brightfield and fluorescent 
microscopy. 
For confocal experiments, approximately 20,000 cells were 
plated in ibidi 8-well micro- scope slides in 250 μL media. 
The cells were allowed to adhere over 24 hours before the 
microbubbles were added. Following this, the cells were 
stained with CellTrace Far Red dye (Life Technologies). 
The dye was obtained as a 50 uL aliquot and suspended in 
9.9 μL DMSO. This was subsequently diluted to 5 μM in 
PBS. Media was aspirated and 250 μL of the dye added. This 
was allowed to incubate for 45 minutes at 37°C before being 
replaced with 250 μL cell culture media. Lucigenin-filled 
microbubbles were then added and allowed to incubate for 
48 hours. 
Images of cell culture were taken on a Nikon Eclipse TS100 
microscope (Nikon UK Ltd., Kingston upon Thames, UK) 
with a Digital Sight DS-2Mv camera and Digital Sight DS- 
L2 control unit. For fluorescent images of lucigenin filled 
microbubbles, Nikon Intensilight C-HGFI UV source was 
used with a FITC filter (excitation 465 - 495 nm, dichroic 
mirror 505 nm, emission 515 - 555 nm).  
For confocal images, a Leica TCS SP5 (Leica Microsystems 
UK Ltd., Milton Keynes, UK) confocal microscope with a 
63×1.4 NA oil immersion lens was used. The sample was 
excited using an Argon laser at 485 nm and emission was 
collected 480 – 550 nm for the green channel and 650 – 750 
for the far red channel. Image processing was done using 
the Fiji package of ImagesJ (National Institutes of Health, 
MD, USA) and Leica LAS AF Lite. 
 
2.11 Delivery of docetaxel 
Free docetaxel and docetaxel-loaded microbubbles were 
incubated for 72 hours in 96-well cell culture before being 
assessed for viability. Experiments were run with 100 nM 
and 10 nM maximum concentrations and were diluted 5× 
serially in media to 0.032 nM and 0.0032 nM respectively.  
The Terason t3000 ultrasound set-up was used as de-
scribed above with a focus of 2 cm. The 96-well plates were 
filled with media (390 µL) to acoustically couple the trans-
ducer to the sample. The plate was sealed using PCR opti-
cal adhesive film (Applied Biosystems, CA, USA). Full con-
tact of liquid in the well with the surface of the seal was 
ensured. The plate was then submerged in a tank of UHP 
water. For insonation, the ultrasound probe was held ap-
proximately 1 cm over the wells for 30 seconds, with the 
bottom of the well plate and then PCR seal within ultra-
sound range. Figure S.6 shows a blank set-up and ultra-
sound insonation of microbubbles in this set up.  
 
3. Results and Discussion  
3.1 Production of lucigenin loaded microcapsules 
It should be expected that the lucigenin loading of the mi-
crocapsules will depend on shell thickness and the material 
composition of the shell. Near-monodisperse SiPCL/silica 
hybrid microcapsules (polydispersity index of 0.226, meas-
ured by DLS) could be produced with shell thickness 
(measured from TEM micrographs) increasing from 28 to 
100 nm with decreasing initial SiPCL concentration in the 
SiPCL/silica feed for the synthesis3. For comparison, the 
S/M/S layered microcapsules had a shell thickness of 65 ± 
7 nm.  
As reported previously3, the SiPCL/silica hybrid shell be-
haves as if it consisted of three layers. SiPCL was added first 
to the polymerization feed, producing a thickness of 24 nm 
after 5 minutes.  Subsequent addition of TEOS to the reac-
tion mixture resulted in the condensation of silica from the 
more highly reactive TEOS. This dominates the reaction 
compared with the slower SiPCL sol-gelation, due to its 
smaller specific volume and lower steric crowding around 
the silicon atom.22–24 The faster deposition in this phase 
means that the differences in shell thickness can mostly be 
attributed to this middle silica-rich layer which is deter-
mined by the proportion of TEOS in the reaction feed. 
However, once the TEOS becomes depleted in the 
polymerization feed (circa 5 hours), residual SiPCL pro-
vides an outer SiPCL-rich coating on the final capsule. In 
contrast, early cessation of the condensation (e.g. after 3 
hours) before depletion of the TEOS, yields a thinner cap-
sule, more comparable with the S/M/S capsule; e.g. 50 wt% 
SiPCL, for the 3-hour synthesis microcapsules yields 77 ± 4 
nm (an inner SiPCL-rich layer, ~24 nm and an outer silica-
rich layer, ~53 nm) vs. 100 ± 13 nm for the 5-hour microcap-
sules. The 3hr capsule is missing the outer more hydropho-
bic SiPCL layer.  
The outside surface of these capsules is therefore expected 
to present a more similar surface to the S/M/S capsules, 
but the difference in external material properties is best 
 demonstrated by zeta potential measurements of the mi-
crocapsules (Table 1).  As can be seen in the table, for zeta 
potential measurements of empty microcapsules the 
S/M/S microcapsules produce a zeta potential that is typi-
cal for colloidal silica in the pH range 6 – 8.25,26 In contrast, 
the 50 wt% SiPCL microcapsule results in a more negative 
zeta potential, indicative of a thicker double layer structure 
and a more stable colloid.  
 
Table 1: Comparison of Zeta potential for capsules 
with and without lucigenin loading.  
Sample 
Capsule wall 
thickness 
(nm) 
Zeta potential (mV) 
Before  
lucigenin 
After  
lucigenin 
50 wt% SiPCL 
(3hr) 77±4 -71.4 ± 1.9 39.1 ± 0.1
 
S/M/S 65±7 -47.1 ± 2.1 -38.9 ± 
0.6 
 
Lucigenin (as a model adsorbant) has previously been 
shown to reach maximum sorption within 5 minutes in sil-
ica microparticles.13 Confocal microscopy of lucigenin-
loaded 50 wt% SiPCL microcapsules (3 hour synthesis) 
showed lucigenin in the shell structure (Figure 1a) and as 
can be seen in Figure 1b, at the lower loading levels for lu-
cigenin (up to 100 µg/batch for S/M/S and 200 µg/batch for 
50 wt% SiPCL microcapsules) the partition of lucigenin be-
tween solution and microcapsule had a strong preference 
for the microcapsules, with almost no lucigenin remaining 
in the supernatant after overnight incubation. 
According to Zaporozhets et al.13 lucigenin adsorbs to silica 
gels according to a Type I Langmuir isotherm (Equation 1).  
 
                 𝑉 = #$%&'()%&'                 (1) 
where the encapsulation of lucigenin (V) is related to the 
equilibrium constant (K1), the equilibrium concentration 
(C) after overnight incubation, and the maximum mono-
layer encapsulation possible (Vm). Since adsorption is lim-
ited by monolayer coverage in this model, the equation 
predicts a plateau in encapsulation at high solution con-
centrations.  However, as can be seen in Figure 1b, this was 
not observed in the experimental data. The adsorption iso-
therm shows two regions with the Langmuir-like adsorp-
tion at low concentrations, whereas at higher concentra-
tions there is a second region where lucigenin loading con-
tinues to increase approximately linearly with equilibrium 
solution concentration above the predicted Langmuir sat-
uration.  
The rather linear increase with equilibrium concentration 
could be indicative of a simple solution partitioning of lu-
cigenin between the external solution and the solution-
filled interior of the capsule. However, taking into account 
the void core and shell volume of the microcapsules, filled 
with the incubating lucigenin solution at equilibrium, this 
only accounts for ~20 µL/batch of 2.4 × 109 microcapsules, 
adding approximately 2% of the equilibrium solution (0.02 
µg/batch/µg/mL) to the overall lucigenin loading. 
 
 
Figure 1: a) Confocal image of the lucigenin-loaded 50 wt% SiPCL 
microbubbles showing that the lucigenin loaded into the shell 
structure. b) The lucigenin loading curve. The encapsulation of 
lucigenin (µg/ 2.4 × 109 microcapsules) is plotted against equilibrium 
solution concentration after incubation overnight. Error bars 
represent the sum of the standard deviations of the equilibrium 
solution concentration and the initial loading concentration. Data is 
fitted to the monolayer model (K2 = 0) for the lucigenin loading data 
and to the multilayer model.  
In contrast, in the second, higher concentration region, 
~35% of the amount in the equilibrium solution is being 
taken up for the 50 wt% SiPCL (0.345 µg/batch/µg/mL of 
lucigenin), whereas the S/M/S microcapsules depends on 
the equilibrium solution concentration (e.g. approximately 
0.353 µg/batch/µg/mL of lucigenin at 200 µg/mL). This 
suggests a multilayer adsorption model for both capsules.  
 In this model, the second layer adsorbs to already adsorbed 
molecules. Equation 2, derived by Wang et al.27 for dye ad-
sorption to sludge particles, has been proposed for such a 
case:  
                    𝑉 = #$%&*(+%,* [() %&+%, *]                      (2) 
Equation 2 allows for the modelling of both single and mul-
tilayer adsorption where K1 represents the equilibrium ad-
sorption constant for the first layer (equivalent to K1 in 
equation 1), and K2 represents the equilibrium adsorption 
constant for the second layer. When K2 = 0, the model as-
sumes the form of Equation 1. As such, the approximate 
monolayer capacities of the microcapsules were obtained 
by fitting both the monolayer model (using the data in the 
low equilibrium solution concentration region), and the 
multilayer model (Figure 1b).  
Both monolayer and multilayer fittings arrived at similar 
Vm values, with the 50 wt% SiPCL microcapsules loading 
significantly more lucigenin than the S/M/S microcapsules 
(Table 2). On the other hand, the multilayer model sug-
gests a greater capacity for multilayer lucigenin loading for 
the S/M/S microcapsules (beyond monolayer saturation). 
These findings highlight that while the first layer of luci-
genin adsorption depends greatly on the microcapsule ma-
terial, overall encapsulation of lucigenin may be limited by 
the physical dimensions of the microcapsule such as pore 
volume. 
 
 Table 2: Mono- and multilayer adsorption fitting re-
sults  
Sample/ 
Model 
Vm  
(µg/batch)  
K1 
(L/µg) 
K2 
(L/µg) R
2 
SiPCL 
Mono 289.6 4.54 × 10
-1 N/A 0.97 
SiPCL 
Multi 272.2 5.03 × 10
-1 6.25 x10-4 0.98 
S/M/S 
Mono 135.6 3.24 N/A 0.95 
S/M/S 
Multi 133.7 3.32 1.26 × 10
-3 0.98 
 
This interpretation can also be considered in the context of 
the data in Table 1 which shows the increase in the zeta 
potential with lucigenin loading.  It is noteworthy, that de-
spite Figure 1b suggesting much higher multilayer loading 
for the S/M/S system, the higher monolayer adsorption 
and surface association of lucigenin with the 50% SiPCL 
(272.2 vs. 133.7 µg/batch), is reflected in the large change in 
zeta potential giving a strongly positive outcome.   
 
3.2 Incorporation into cells 
We have previously shown that, unlike the normal lipid 
based ultrasound contrast agent, microbubbles produced 
from these materials are exceptionally stable candidates 
for ultrasound contrast agents. They show a strong 
backscatter signal within the medically approved range of 
acoustic pressure3,20 and in contrast to the lipid capsules 
that generally become acoustically inactive a few hours af-
ter reconstitution, they show no deterioration even after 
several hours, unless a degradable chemistry (such as the 
caprolactone) has been inbuilt.3  Furthermore, the elastic-
ity of the bubbles could be altered by incorporation of dif-
ferent organosilanes and, together with control of the bub-
ble shell thickness, both the backscatter intensity and the 
ultrasound pressure required for bubble rupture could be 
tuned.  In the case of the materials used here, no suscepti-
bility to rupture was found for a mechanical index (MI) < 
0.8.3  
Thus, the lucigenin loaded microbubble offers an interest-
ing model for dual function of US contrast agent and deliv-
ery vehicle.  After loading with lucigenin, the microbubbles 
(2 × 106 microbubbles/mL loading of 200 μg luci-
genin/batch) were incubated with C4-2B prostate cancer 
cell samples. Even after washing with PBS, a high number 
of microbubbles remained firmly adhered to the cells. Fig-
ure 2c and 2f shows the overlaid images indicating that the 
cells were healthy and properly adhered to the bottom of 
the dish with a clear affinity for a number of the microbub-
bles to associate with the C4-2B cells, especially in the case 
of SiPCL, where they associated in clusters. The overlay im-
age also suggests the colocation of many of the microbub-
bles with the stained cytoplasm. Z-stacked images taken 
through the cells, is consistent with some of these mi-
crobubbles becoming incorporated into the cell as shown 
in Figure 2g, where the white arrow indicates one area 
when microbubbles have become enclosed within the cell. 
However, the Cell Trace Far Red dye stains primary amines 
in, for example, proteins, but it appears from the confocal 
image that the microbubbles are not in a stained compart-
ment, which may indicate that they are not internalized in 
the cytosol. Internalization of large macromolecules has 
been reported to occur through macropinocytosis, as a 
non-specific event that internalizes a large volume of ex-
tracellular fluid.28,29  
Although these data indicate some promise for the mi-
crobubbles as drug delivery vehicles, the C4-2B cell system 
is too complex to be able to characterize the lucigenin re-
lease profiles and draw any conclusions about the release 
model.  In the first instance, therefore, a simple solution 
based model was examined to characterize the release and 
thence the effect of ultrasound.
  
  
Figure 2:  Microscope images of the lucigenin-filled microbubbles incubated with C4-2B prostate cancer cells showed colocation with cells. a) 
brightfield, b) fluorescent and c) brightfield/fluroescence overlay images of the lucigenin-filled 50 wt% SiPCL microbubbles and d) brightfield, e) 
fluorescent and f) brightfield/fluorescence overlay images of the S/M/S microbubbles show colocation with cells. g) 3D reconstruction of z-
stacked images taken with a confocal microscope were suggestive of microbubble internalization. See Figure S.7 for z stack images.   
 
  
Figure 3: Release profiles of lucigenin-loaded (a) S/M/S and (b) 50 wt% SiPCL microcapsules and microbubbles. Korsmeyer-Ritger-Peppas 
release model of lucigenin-loaded (c) S/M/S and (d) 50 wt% SiPCL microcapsules and microbubbles of high (500 µg/mL) and low (100 µg/mL) 
lucigenin loading. 
3.3 Delivery of lucigenin 
To study the release of lucigenin from these vehicles, 
leaching into a background PBS solution was examined. 
Two loading solutions with 500 and 100 µg/mL were 
tested, and are referred to as “high” and “low” respectively 
(Table 3) and both microbubbles (with core solvent evap-
orated and replaced with air) and microcapsules (prior to 
desiccation) were examined to determine if the desicca-
tion process affected the release profile. The slight in-
crease in burst release from microbubbles was attributed 
to lucigenin redistribution during the drying process to 
the outside of the sample thus the higher availability re-
sulted in a higher burst release.30 For S/M/S samples, 
once the dissolution/desorption front entered the pores 
of the microcapsules during release, the release rate in-
creased so that at the end of 3 hours the release from mi-
crobubbles and microcapsules were similar. However, a 
separate phenomenon was observed for 50 wt% SiPCL 
samples. The low release from microcapsules by the end 
of 3 hours suggested that the adsorption of lucigenin to 
wet SiPCL is a lot stronger than to dry SiPCL.  It can be 
seen that delivery of lucigenin from the S/M/S bubbles 
and capsules is similar in all cases (Figure 3a), whereas 
the 50% SiPCL shows distinct characteristics for both mi-
crobubble and microcapsule as well as high and low load-
ing (Figure 3b).  
 
Table 3: Details of microcapsules/microbubbles 
tested for sustained delivery 
Sample Loading Solution (µg/mL) 
Loading  
(µg/batch) 
50 wt% SiPCL 
500 259 ± 10 
100 99 ± 0 
S/M/S 
500 159 ± 3 
100 93 ± 0 
 
  
Figure 4: Log-log plots of a) high and b) low lucigenin loading of S/M/S microbubbles and microcapsules; c) high and d) low lucigenin loading of 
50 wt% SiPCL microbubbles and microcapsules with associated linear fits to the regions of the Weibull equation (𝑚 = 0102). The data is separated 
out into three colors for easy visualization of the three time sections of 0 – 4 minutes, 4 – 10 minutes, and 10 – 180 minutes.   
 
The differences between capsule and bubble for the 50% 
SiPCL could be due to swelling of the polymer matrix 
when the dry bubble is put in the aqueous environment, 
leading to Class II diffusion.31 The microcapsules are dried 
after lucigenin loading, producing a microbubble con-
taining an air core, whereas the microcapsules are liquid-
filled.  Compared with silica gel, which is hydrophilic and 
hygroscopic, but still well known for its non-swelling be-
havior after drying,32 SiPCL is more hydrophobic, which 
should also point to little swelling in water, so that more 
Fickian than Class II diffusion would be expected to dom-
inate.3 If the payload release is simple diffusion 
with/without swelling, the Korsmeyer-Peppas/Ritger-
Peppas models, which are semi-empirical diffusion based 
models, attempt to distinguish a diffusion release mech-
anism appropriate for a spherical vehicle: 
 
                 𝑙𝑜𝑔 0102 = 𝑙𝑜𝑔𝛼 + 𝑛𝑙𝑜𝑔𝑡                (3) 
where Mt/M∞ describes the fraction of lucigenin released 
at time t, a is a constant which depends on the geometric 
and structural properties of the system and n provides in-
formation on the release mechanism (Fickian n ≤ 0.43 
(sphere); mixed 0.85 ≤ n ≥ 0.43; Case II n ≥ 0.85).After an 
initial burst (t < 4 minutes) which is often characteristic 
of systems with a layer of loosely associated molecules on 
the outside surface5,33,34, Figure 3c shows a reasonable lin-
ear fit for the S/M/S system at t > 4 minutes with n (Equa-
tion 3) in the range of 0.44 – 0.48 for the microcapsules 
and 0.29 – 0.33 for the microbubbles. This may be intui-
tive with the idea that the number of adsorption sites be-
tween lucigenin and S/M/S is relatively small (note Vg is 
smaller than for SiPCL, although the multilayer load is 
high) and the initial payload concentration is below its 
solubility limit and dissolves readily in solution within 
 the matrix, so that it presents as a monolithic solution, 
where the release is controlled by diffusion through the 
matrix.35  
In the case of 50% SiPCL, Figure 3d shows that the data 
do not fit a single linear relationship.  However, some fea-
tures become evident from these plots.  The initial release 
(compared at 1 minute, log(t) = 0) is higher for the mi-
crobubble than the microcapsule, inferring some rapidly 
removed surface dried material. The data can be fitted to 
a linear approximation for 4 < t < 10 minutes, with 0.55 < 
n < 0.59 for both bubbles and capsules, whereas for t > 10 
minutes there is a clear distinction between the bubbles 
and the capsules (microcapsules: 0.30 > n > 0.27; mi-
crobubbles: 0.55 > n > 0.40).  For low concentrations of 
loaded lucigenin n = 0.50 – 0.55 for t > 4 minutes; this is 
close to the Fickian diffusion model. This may reflect the 
simple monolayer adsorbate model, with concentration 
below the solubility limit, whereas for the multilayer (as 
typical in polymeric delivery vehicles) additional com-
plexities usually occur with mixed processes of diffusion 
and dissolution or desorption and leaching, so that other 
approaches are needed to examine these data.
 
Figure 5: (a) Graph of b-values derived from Weibull model fitting for 50 wt% SiPCL and S/M/S microbubbles and microcapsules demonstrating 
the different regimes of lucigenin release. Release regimes as developed by Papadopoulou et al.36 (b) From Equation 5 the 63.2% dissolution time 
(Td) is given for −ln	(1 − 0102) = 1 or logTdv= (loga)/b. 
  
For example, the Weibull function is a stretched expo-
nential that has no theoretical basis but has been used 
extensively to examine drug dissolution and release and 
is able to deal with a fit to data where fractal geometry 
plays a role36–38: 
                  0102 = 1 − 𝑒𝑥𝑝	(−𝑎𝑡E)           (4) 
 
 𝑙𝑜𝑔 − 𝑙𝑛 1 − 0102 = 𝑏 𝑙𝑜𝑔 𝑡 + 𝑙𝑜𝑔	(𝑎)             
                                                                         (5) 
where a and b are both constants. It has been shown that 
b can provide insight into the mechanism of diffusional 
release. Specifically, decreases in the value of b (Papado-
poulou et al.36) have been shown to represent the slowing 
down of the diffusion, and has been attributed to increas-
ing disorder of the encapsulating matrix. Durdureanu-
Angheluta et al39 have also derived a fractal “diffusion” 
equation which has the same form as the Weibull func-
tion where they have sought to derive the empirical con-
stants, so that a and b are related to the fractal trajecto-
ries where b = 2/DF (DF is the fractal dimension of the 
sphere). 
The linearized version of the Weibull function (Equation 
5) shows different linear regions (Figure 4), with slopes 
(b) that can be used to follow the trends with time at-
tributed to the diffusion space character36. In this case 
(Figure 5a) the Weibull function generally predicts a 
trend for diffusion from normal Euclidean space at short 
times tending towards diffusion out of fractal spaces with 
increasing time.  The microbubbles showed a greater 
trend to more disordered space compared with the mi-
crocapsule, which may be associated with the wetting of 
the pore spaces and dissolution of the lucigenin from the 
inner cavity surface.  
In some cases, e.g. for the low concentration lucigenin 
loading, the two regions for t > 4 minutes are less distinct 
(also seen in Figure 3), consistent with the loaded luci-
genin being below the solubility limit and diffusing from 
solution within the matrix. In this instance, the Higuchi 
model should provide a good fit. Higuchi used pseudo 
steady state assumptions to describe drug release in a ma-
trix based on Fick’s law showing a square root time de-
pendency, which was modified by Baker and Lonsdale40 
for a spherical matrix: 
 
               GH 1 − 1 − 0102 H/G − 0J02 = 𝑘𝑡       (6) 
where 𝑘 = GL$*$M,*N  
 
Dm describes the diffusion in the matrix of radius r, C0 is 
the starting concentration with solubility in the matrix 
Cm. Figure 6 plots the data according to this model and 
provides a reasonable fit for the S/M/S microcapsule 
where the payload is already in solution, below the solu-
bility limit (Figure 6b). This plot also reveals the initial 
burst for the microbubble followed by a period of sus-
tained release (t < 80 minutes) with a similar slope (k 
from Equation 6) to that found for the microcapsule for t 
< 180 minutes. This would be expected if Dm, Cm and C0 
are the same in both cases, once the burst release of luci-
genin from the outside of the bubble is over.   
In the case of the SiPCL containing vehicles, the low con-
centration microcapsule data also achieves an approxi-
mate fit to this model (R2 = 0.992), but with a noticeable 
upward curvature from linearity (Figure 6d).  The surface 
hydrophobicity of these bubbles has been reported previ-
ously by us,3 and this may be associated with the more 
hydrophobic characteristics, slowing the wetting and dis-
solution of lucigenin. 
It is also clear that according to Equation 6, k ~ 1 × 10-4 for 
the S/M/S system, whereas for the SiPCL it is of lower 
magnitude (k ~ 4 × 10-5). This points to lower solubility 
and/or a lower diffusion in this matrix. 
In contrast to the low loaded lucigenin capsules and bub-
bles, none of those that are loaded beyond the predicted 
Langmuir monolayer limit fit the Baker-Lonsdale model 
(Figure S.8). Looking again at the Weibull plots, it can be 
seen that at this loading, there is greater distinction of 
the three zones for the SiPCL system. For t > 30 minutes, 
the 50 wt% SiPCL samples enters a very slow but sus-
tained release period, with b values lower than those de-
rived in the S/M/S formulation (Figure 5a) and labelled 
as being from “highly disordered space”. This is at-
tributed to dissolution and diffusion of adsorbed luci-
genin from the amorphous SiPCL-rich layer (a much 
higher Vm is seen for SiPCL than S/M/S). For these data 
the predicted dissolution time (Td) reveals a distinct dif-
ference compared with the low concentration loaded 
SiPCL containing vehicles, with an increase in predicted 
Td from 1 – 2 days for the low loaded 50% SiPCL system 
(and the S/M/S system for any loading) to 10 days for the 
high loaded SiPCL microbubble and > 20 days for the mi-
crocapsule. 
  
Figure 6: Baker and Lonsdale release profiles for low loading microcapsules and microbubbles of a) S/M/S and b) 50 wt% SiPCL. 
3.4 Ultrasound enhanced release of lucigenin 
The slow release for the 50% SiPCL after 30 minutes can be 
beneficial when delivery of reagent is desired over an ex-
tended period. Compared with the S/M/S model the total 
loading of lucigenin into this capsule is increased by > 160% 
so the capacity is also good. Furthermore, the microbubble 
offers an excellent model for examination of the effect of 
ultrasound on the release profile.  Figure 7 compares the 
release profile with and without ultrasound insonation and 
shows that in the presence of insonation release is in-
creased.  This suggests that ultrasound could be used as a 
release trigger. From the Weibull function (Figure 7b), a 
strong change in the plot for the 50% SiPCL microbubble 
is evident, resulting in an increase in release rate, mani-
fested by increase in the value of b towards fractal space 
(Figure 5). Under ultrasound control, the resultant value of 
Td is reduced from 10 days to 2 days.  This linear plot in this 
case extends the sub-30 minute trend and is nearly coinci-
dent with the data for the S/M/S system without ultra-
sound. The S/M/S microbubble with ultrasound also over-
lays these data and therefore unsurprisingly, demonstrates 
little change with ultrasound for this material. 
The difference between the data are also found in the Baker 
Lonsdale plot which better separates the S/M/S data with 
and without ultrasound.  From the slopes of the plot for 30 
< t < 60 minutes ultrasound insonation increases k to ~2 × 
10-4 and reduces the release time.  According to Equation 
6, this indicates that the effect of ultrasound is either im-
proved solubility or improved diffusion. 
We have shown previously that the microbubbles are able 
to withstand extensive insonation in the same frequency 
and power range as used here, without breakage.3 Thus, the 
enhancement in release could have been due to mi-
crostreams generated off the surfaces of microbubbles un-
dergoing sustained cavitation. The microstreams may have 
acted to promote transport of lucigenin away from the mi-
crobubble for improved desorption and dilution into the 
flowing PBS.41 Additionally, it may have been possible that 
small oscillations of the cavitating microbubble loosened 
trapped lucigenin.42–44 A third potential mechanism where 
ultrasound is used in release improvement is local heating 
due to prolonged insonation.45 However, in the experi-
ments undertaken here, the insonation is achieved within 
the limits required for low power medical ultrasound and 
no evidence of local heating was found. 
3.5 Testing the microbubbles in C4-2B cell culture with US 
Since the lucigenin did not appear to affect the growth of 
C4-2B cells (Figure 2), we used the findings from this 
model to design a docetaxel filled microcapsule.  The 
empty microbubbles and microcapsules were found not to 
be toxic to the cells at concentrations below 1.0 × 109 mi-
crocapsules/mL (Figure S.9).	 This is approximately 40 
times the normal ultrasound imaging concentration, and 
showed cell viability at 72 hours of 107.9 ± 5.7% and 109.7 ± 
5.1% for the 50% SiPCL and S/M/S microcapsules respec-
tively. This non-toxicity was not changed as a result of in-
sonation. 
For docetaxel in free solution, the threshold for cell toxicity 
was dependent on both time and concentration (Figure 
S.10) with a EC50 around 2 nM for 72 hours. The time effect 
of docetaxel was previously reported in other cell lines and 
has been attributed to the activation of the apoptotic path-
way by the drug, through the inhibition of microtubule de-
polymerisation between the G2 and M phase of the cell cy-
cle.46 With longer times more cells have reached the G2/M 
stage and become susceptible to docetaxel toxicity. The use 
of US insonation did not significantly affect docetaxel tox-
icity.  
 
 
 Figure 7: (a) Baker and Lonsdale and (b) Weibull release profiles for high loaded 50% SiPCL and S/M/S microbubbles before and after 
insonation. Ultrasound insonation was initiated 30 minutes after the start of the release of lucigenin and data is plotted with respect to the 
release at 30 minutes and compared with data recorded without insontation.    
Following the protocol given in Section 2.11, treating the 
microbubbles with 200 µg/batch docetaxel solution pro-
duced a docetaxel loading of 27.0 ± 8.7 µg/batch and 36.1 ± 
10.8 µg/batch for the 50% SiPCL and S/M/S microbubbles 
respectively. The release of docetaxel from the microcap-
sules and microbubbles, based on the cell viability plots 
(Figure 8a and b) suggest an EC50 equivalent of circa 10 nM 
(at 72 hours) in terms of the total payload concentration 
encapsulated in the microcapsule or microbubble.  This is 
also indicative that total release of the docetaxel is not 
completed in 72 hours.  
If the cell viability is observed at 2 nM total docetaxel con-
centration (which is around the EC50 for docetaxel in solu-
tion but at the threshold of the toxicity curve at 72 hours 
for the docetaxel loaded capsules and bubbles) then it can 
be seen that at 120 hours a difference emerges between the 
microcapsules and microbubbles (Figure S.11). Whereas 
the cell viability has dropped to 50% for the microcapsules 
(equivalent to solution administered docetaxel), it remains 
above 80% at this concentration for the bubbles. This fol-
lows a similar trend to the projections for lucigenin release 
(Section 3.3), which showed a long period of slow release 
at high lucigenin loadings with Td up to 20 days for the mi-
crocapsule.  
Based on these findings, it is clear that the effect of US 
needs to be examined at docetaxel loadings below the ap-
parent EC50 for the microbubbles (i.e. < 10 nM). Preliminary 
results, Figure 8c and d show the effect at 72 hours, follow-
ing insonation for 30 seconds. As can be seen from these 
data there is a clear impact even at 0.2 nM, where the mi-
crobubble in the absence of docetaxel or the free solution 
drug or the solution drug combined with empty microbub-
bles usually show any cell toxicity.  This finding will require 
much further investigation to separate the effects due to 
US induced cell permeabilisation and enhanced docetaxel 
release from the microbubbles, but the association of the 
microbubbles with the cells, combined with the effect of 
ultrasound on both the microbubble and the cell appears 
to be providing a locally high effective docetaxel concen-
tration. 
4. Conclusions 
This work has followed the adsorption and release of luci-
genin from SiPCL and S/M/S microcapsules and microbub-
bles as a ‘drug’ model to investigate the capsules and bub-
bles as a drug delivery vehicle.  The adsorption was seen to 
be able to achieve greater than monolayer coverage, de-
pending on solution concentration.     Delivery of the luci-
genin from the capsules and bubbles occurs with an initial 
burst release, dissolving material below its solubility limit, 
so that it presents as a monolithic solution, where the re-
lease is controlled by diffusion through the matrix. Further 
delivery from the matrices shows some features of Fickian 
diffusion at low concentration loadings. At higher concen-
trations Fractal geometry appears to make an increasing 
impact on the release as indicated using the Weibull em-
pirical function. The microbubbles showed a greater trend 
to more disordered space compared with the microcap-
sule, which may be associated with the wetting of the pore 
spaces and dissolution of the lucigenin from the inner cav-
ity surface. 
In contrast to the S/M/S systems, which showed Td of 1 – 2 
days, the 50 wt% SiPCL samples at high concentration 
loadings show a slow but sustained release period with a Td 
of ~10 days for the microbubbles (> 20 days for the micro-
capsules), with b values indicating release from highly dis-
ordered space, attributed to the amorphous SiPCL-rich  
  
Figure 8: Cell viability of C4-2B cells showed that docetaxel released from (a) 50 wt% SiPCL and (b) S/M/S microcapsules and microbubbles was 
incomplete at 72 hours. Preliminary results with US insonation of (c) 50 wt% SiPCL and S/M/S microbubbles suggest enhanced delivery < 10 nM. 
The docetaxel concentration axis refers to the total equivalent docetaxel concentration encapsulated, not the released concentration.  
layer.  These data are promising for long period sustained 
drug release. Furthermore, these microcapsules could be 
triggered to increase their release rate by ultrasound in-
sonation. Using data acquired with a standard portable 
medical ultrasound imaging system, the model predicted a 
reduction of Td from 10 to 2 days. Based on these predic-
tions a protocol was developed for loading the capsules and 
bubbles with docetaxel that were incubated with C4-2B 
cells. The effect of ultrasound within the medically used 
imaging range, on docetaxel filled microbubbles showed 
an increase in cell toxicity, even at concentrations below 
the usual solution threshold. This has potential in causing 
enhanced local delivery of a drug by ultrasound triggering. 
The mechanism for this effect, as well as the effect of vari-
ous ultrasound parameters needs further investigation, but 
may be the result of oscillation induced dissolution of the 
payload or enhanced transport of the lucigenin/docetaxel 
from the capsule in the microstreams generated at the sur-
face of the bubble, 
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Supplementary information 
 
 
Figure S.1: FT-IR spectra of PCL diol (as supplied) and SiPCL synthesized. The SiPCL FT-IR spectra 
showed the appearance of an urethane linkage as determined by the N-H and C-N bend at 1525 cm-1 (●), 
and the appearance of the triethoxysilane end-cap by Si-O-C bend at 1078 cm-1 (■), and Si-C stretch at 
780 cm-1 (♦). 
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Figure S.2: Lucigenin calibration curve correlating fluorescence emission in water and lucigenin concen-
tration.  
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Figure S.3: Docetaxel calibration curve correlating absorbance and docetaxel concentration in ethanol.   
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Figure S.4: Lucigenin calibration curve correlating fluorescence emission in 0.01 M PBS and lucigenin 
concentration.  
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Cell Viability Assay 
Due to the high density at which the microbubbles were added to some wells, an absorbance reading at 
490 nm was taken immediately prior to MTS addition. This reading served as the background from which 
the later MTS signal was subtracted. Following this, 20 μL of MTS was added to each well and was 
allowed to develop over 2 hours before the absorbance at 490 nm was taken again. The absorbance read-
ings were taken on a Tecan Infinite M200 using i-control version 1.9 (Tecan Group Ltd., Männedorf, 
Switzerland), and the percent viability was calculated as follows:  %𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 = 𝐴𝑏𝑠UVWX − 𝐴𝑏𝑠UMY𝐴𝑏𝑠Z,UVWX − 𝐴𝑏𝑠Z,UMY 
where Abspre and Absc,pre are the absorbance of the sample and the control before the addition of MTS, and 
Abspost and Absc,post are the absorbance of the sample and control after 2 hours of incubation with MTS. 
This small correction decreased the effect of the microbubble interference of absorption at 490 nm.  
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Figure S.5: Radio frequency (RF) results of the microbubbles were collected to understand the nature of 
the response and the frequency range of the ultrasound machine. Raw results of the microbubbles were 
normalized to a control of plain water. The peak fitting of the normalized RF response spectra of a) S/M/S 
(7.33 MHz, RMS = 0.26) and b) 50 wt% SiPCL (7.30 MHz, RMS = 0.027) microbubbles insonated with 
the “high” frequency setting to a single peak is shown above. No bubble rupture was observed following 
insonation. 
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Figure S.6: Representative ultrasound image of a) blank, and 3 ×107 microbubbles/mL of b) 50 wt% 
SiPCL and c) S/M/S microbubbles in the well plate set-up. The wells are outlined in red.  
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Figure 
S.7: Merged z-stack images of 50 wt% SiPCL microbubbles incubated with C4-2B cells were suggestive 
of microbubble internalization.  
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Figure S.8: Baker and Lonsdale release profiles for high loading a) S/M/S and b) 50 wt% SiPCL mi-
crobubbles and microcapsules.  
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Figure S.9: Cell viability of C4-2B cells with respect to microbubble concentration after 72 hours incu-
bation.  
  
 
 
28 
 
Figure S.10: Optical micrographs of C4-2B cells incubated with (a) blank and (b) docetaxel-loaded 50 
wt% SiPCL microbubbles for 48 hours. Both images were taken at 400× magnification. c) demonstrates 
the effect of time and of docetaxel concentration on cell viability.  
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Figure S.11: Cell viability of C4-2B cells after 72 and 120 hours of incubation with a) microcapsules and 
b) microbubbles of 50 wt% SiPCL and S/M/S formulations, normalized to the cell viability of the same 
concentration of free docetaxel at those times.  
 
 
